Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.
Method Article
Inducing rapid liver hypertrophy using Associating Liver Partition and Portal vein ligation for a Staged hepatectomy (ALPPS) has been proposed for resection of borderline resectable liver tumors. This model may elucidate mechanisms involved in rapid hypertrophy and allows testing of drugs that promote or block the acceleration of regeneration.
Recent clinical data support an aggressive surgical approach to both primary and metastatic liver tumors. For some indications, like colorectal liver metastases, the amount of liver tissue left behind after liver resection has become the main limiting factor of resectability of large or multiple liver tumors. A minimal amount of functional tissue is required to avoid the severe complication of post-hepatectomy liver failure, which has high morbidity and mortality. Inducing liver growth of the prospective remnant prior to resection has become more established in liver surgery, either in the form of portal vein embolization by interventional radiologists or in the form of portal vein ligation several weeks prior to resection. Recently, it was shown that liver regeneration is more extensive and rapid, when the parenchymal transection is added to portal vein ligation in a first stage and then, after only one week of waiting, resection performed in a second stage (Associating Liver Partition and Portal vein ligation for Staged hepatectomy = ALPPS). ALPPS has rapidly become popular across the world, but has been criticized for its high perioperative mortality. The mechanism of accelerated and extensive growth induced by this procedure has not been well understood. Animal models have been developed to explore both the physiological and molecular mechanisms of accelerated liver regeneration in ALPPS. This protocol presents a rat model that allows mechanistic exploration of accelerated regeneration.
The size of the liver remnant limits the resectability of liver tumors.1 In general, when less than 25% liver tissue is left behind, the patient is at increased risk of death from acute liver failure due to the lack of metabolic function for the entire organism ("too small for size syndrome").2 This post-hepatectomy liver failure is the most devastating complication after liver resection. Therefore clinicians have tried to induce liver regeneration prior to resection of the liver by manipulating the flow of the portal vein.3 It was found that, once the portal vein is occluded, the remaining part with portal vein flow starts to grow at a slow rate, and can thereby increase up to 60% in size.4 Surgical ligation5 or interventional portal vein occlusion have both been clinically established.4 The increase in volume and function of the liver is reliable, but the growth rate of the liver after portal occlusion is only about one fifth compared to the growth of the remnant liver after partial hepatectomy.6
The time necessary for the liver to grow is weeks to months even though the liver can regenerate at a much faster rate after resection. As such, the liver is the only organ that grows back to normal function after removal of a part of it.7 A novel procedure inducing liver regeneration at a similar pace as after partial hepactectomy was developed by a group of surgeons who discovered that adding a transection between the occluded and the non-occluded part of the liver induces liver hypertrophy at the same growth rate as after liver resection, but prior to resection.9 The procedure initiates rapid hypertrophy of 80% within a week in the future liver remnant, which allows the resection of extensive, primarily unresectable, liver tumors within a week. The procedure was called "Associating Liver Partition and Portal vein ligation for Staged hepatectomy = ALPPS" and became rapidly popular across the world.10 Multiple reports supported an expansion of the resectability of borderline resectable liver tumors achieved by the new technique,11 while the complex surgical procedure was also criticized for its high complication rate.12,13
The development of a rodent and also large animal models of slow and rapid hypertrophy has been attempted since the publication of ALPPS in 2012 to allow a better histological characterization and understanding of the mechanisms and to test drug effects on the different growth rates of liver tissue in animals. The first animal model developed was a rat model. In this model, rapid hypertrophy after parenchymal transection between the right and the left part of the median lobe accelerated regeneration of the right median lobe.14 A different model was introduced later in the mouse. In this model the left lateral lobe was resected and the portal vein branches to every lobe of the liver except the left median lobe were tied.15 In the meantime, large animal models of ALPPS in pigs have been described as well.16
For the study of physiological mechanisms like flow changes and pressure in the portal vein, perfusion and oxygenation of liver tissue, the rat model is superior to the model of ALPPS in mice. Another advantage of the rat over the murine model is that in the rat model there is no necessity for a resection of the left lateral lobe,15 which may contaminate the effects of liver resection with those of ALPPS. The rat model in contrast does not reduce the liver cell mass. A pig model uses the right posterior lobe as the growing lobe, but the pig liver is highly lobulated. Therefore, it is difficult to create a transection plane in the already thin tissue bridge between the right posterior and the right anterior lobe. In contrast, the median lobe in rats consist of two parts that are separately supplied by a portal vein each and a parenchymal transection plane can easily be created between the two using microsurgical techniques. The availability of small animal computer tomography (CT) and/or magnet resonance imaging (MRI) allows the very exact quantification of volumetric growth between portal vein ligation alone and portal vein ligation and the added transection, which is important for the validation of any rapid liver hypertrophy model.
The protocol presented here describes the surgical technique and procedures used for volumetric validation and physiological characterization of the model of slow and rapid hypertrophy after portal vein ligation and portal vein ligation with transection, respectively, in rats.
All experiments in this protocol were approved by the Veterinary Authorities of the Canton of Zürich, Switzerland (number 60/2014). Furthermore, all experimental steps were performed in strict compliance with the Guidelines on Experiments with Animals by the Swiss Academy of Medical Sciences (SAMS) and Guidelines of the Federation of European Laboratory Animal Science Associations (FELASA).
1. Animal Husbandry, Operating Room Equipment and Instruments, Anesthesia
2. Start of Surgery
3. Portal Vein Ligation (PVL)
4. Portal Vein Ligation with Transection (PVL+T)
5. Intraoperative Measurement of Portal Vein Pressure and Volume Flow
6. Final Steps of Surgery
7. Liver Volumetry in Rats Using Small Animal CT
The two different surgical procedures portal vein ligation (PVL) and PVL with transection (PVL+T) result in distinctly different growth kinetics. PVL induces moderate volume increase within 3 days, whereas in PVL+T a much larger right median lobe (RML) can be seen (Figure 5). This can be verified by daily volumetry. The volume of the RML roughly doubles within 3 days in PVL, while it triples in PVL+T.17
This protocol presents an animal model of ALPPS with its rapid hypertrophy induced by PVL+T, that roughly doubles volume increase within 3 days compared to PVL alone.17 The right middle hepatic lobe is used as a model for the growing liver lobe because the middle hepatic lobe is one contiguous parenchymal mass supplied by two separate portal veins to its left and to its right side, as shown in Figure 1 in a recently published work.17 Compared t...
The authors have nothing to disclose.
The authors have no acknowledgements.
Name | Company | Catalog Number | Comments |
Isoflurane, 250 mL bottles | Attane, Piramal, Mumbai, India | LDNI 22098 | Standard vet. equipment |
Tec-3 Isofluorane Vaporizer | Ohmeda, GE-Healthcare, Chicago, IL | not available anymore | Standard vet. equipment |
Buprenorphine (Temgesic) | Indivior, Baar, Switzerland | 7680419310353 | GTIN-number |
Vitamine A ointment | Bausch&Lomp, Zug, Switzerland | 7680223980247 | GTIN-number |
Atropine sulfate 0.5 mg/mL | Sintetica SA, Mendrisio, Switzerland | 7680565330045 | GTIN-number |
Microsurgery microscope | Olympus, Tokio, Japan | SZX10 | Standard vet. equipment |
Betadine | Mundipharma, Basel, Switzerland | 7680342821377 | GTIN-number |
Sponges | Carl Roth GmbH, Karlsruhe, Germany | NK83.1 | Mini-sponges |
Abdominal Wall retractors | N/A | N/A | Self-made from paper clips and Q-Tips |
3-0 silk | Ethicon, Sommerville, NJ | K872H | Standard surgical |
Scissors | World precision instruments (WPI), Sarasota, FL | 503371 | Standard microsurgical |
Adson forceps | World precision instruments (WPI), Sarasota, FL | 501244-G | Standard microsurgical |
Fine tips microforceps | World precision instruments (WPI), Sarasota, FL | 501976 | Tips need to be polished regularly |
Curved fine tips microforceps | World precision instruments (WPI), Sarasota, FL | 504513 | Essential to go around the portal vein branches |
6-0 LOOK black braided silk | Surgical Specalities Corporation, Wyomissing, PA | SP114 | Spool, precut prior to the procedure |
2-0 silk sutures | Ethicon, Sommerville, NJ | K833 | Standard surgical |
5-0 maxon sutures | Covidien, Dublin, Ireland | 6608-21 | Standard surgical |
Bipolar microforceps | Sutter, Freiburg, Germany | 780148SGS | Essential for parenchymal transection |
Q-tips small | Carl Roth GmbH, Karlsruhe, Germany | EH11.1 | Standard surgical |
Q-tips big | Carl Roth GmbH, Karlsruhe, Germany | XL54.1 | Standard surgical |
G30 needle | Terumo, Tokyo, Japan | NN-3013R | Standard anesthesia equipment |
2 mm volume flow probe | Transonic Systems, Ithaca, NY | MA-2PS | Smallest available probe for HAT-311 flow meter |
Transonic flow meter | Transonic Systems, Ithaca, NY | HAT-311 Transsonic flow QC meter | One of the first generation flow flow meters for surgery |
ExiTron nano 12,000 | Miltenyi Biotech, Bergisch Gladbach, Germany | 130-095-698 | Nanomoloecular contrast medium that opacifies liver and spleen |
G26 intravenous catheter | Becton Dickinson, Franklin Lakes, NJ | 391349 | Standard anesthesia equipment |
Quantum FX MicroCT | Perkin Elmer, Waltham, MA | N/A | Standard small animal CT scanner at the institute of physiology, University of Zürich |
OsiriX 8.0 | Pixmeo Sarl, Geneva, Switzerland | N/A | Public domain software : www.pixmeo.com |
Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE
Zapytaj o uprawnieniaThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone